Core Viewpoint - The company Daren Tang announced the transfer of its equity stakes in Tianjin Shike, resulting in a significant financial gain and a strategic shift towards focusing on its core business operations [1][3]. Group 1: Transaction Details - Daren Tang transferred 4.6% and 7.4% stakes in Tianjin Shike to Helion (China) and Haleon CH SARL, respectively, for a total transaction price of approximately 1.623 billion RMB [1]. - The transaction price reflects a 35% premium on the asset valuation, leading to an estimated investment income of about 1.54 billion RMB for Daren Tang [1]. - Post-transaction, Daren Tang will no longer hold any equity in Tianjin Shike [1]. Group 2: Financial Impact - The transaction is expected to increase Daren Tang's net profit by 1.3 billion RMB after tax, positively impacting its 2025 net profit outlook [1]. - In the previous year, Daren Tang had also sold a 13% stake in Tianjin Shike, generating a profit of 1.759 billion RMB, which contributed to a 125.94% year-on-year increase in net profit [1]. - Despite the profit from the stake sale, Daren Tang's non-recurring net profit declined by 21.62% year-on-year, marking the first negative growth in seven years [1]. Group 3: Company Performance - Daren Tang's revenue has been declining for two consecutive years, with only one core product, Qingyan Diban, showing sales growth of 37.06% in 2024 [3]. - Other products, including Jingwanhong Ointment and Zilong Jinjian, experienced significant sales declines, with some products seeing over 10% drop in sales volume [3]. - The company aims to utilize the funds from the transaction for business expansion, including strategic acquisitions, R&D projects, and market development [3]. Group 4: Tianjin Shike's Performance - Tianjin Shike reported a revenue of 3.582 billion RMB and a net profit of 982 million RMB in 2023, with projected revenues of 3.559 billion RMB and net profits of 711 million RMB for 2024 [2]. - Tianjin Shike's strong performance has been a significant contributor to Daren Tang's overall profits, accounting for 30% of its total profit in 2023 [3].

Core Viewpoint - Daren Tang plans to sell its 12% stake in Tianjin Sihke Pharmaceutical Co., Ltd. for a total price of 1.623 billion yuan, marking a complete exit from the shareholder list of Tianjin Sihke [1] Group 1: Transaction Details - The transaction is expected to bring an investment gain of 1.54 billion yuan for the current period [1] - Daren Tang's market capitalization is 23.462 billion yuan, with a previous closing price of 30.47 yuan [1] - The stake is being sold to Helion (China) Co., Ltd. and Haleon CH SARL [1] Group 2: Financial Implications - The sale represents a significant short-term financial gain for Daren Tang, which had previously earned 245 million yuan from this investment in 2023, accounting for 25% of the company's net profit [1] - The funds from the transaction are intended for business expansion, including strategic acquisitions, R&D projects, new product development, market expansion, and general corporate purposes [1] Group 3: Business Performance Challenges - Daren Tang's main business performance is declining, with industrial revenue of 4.491 billion yuan, down 437 million yuan year-on-year, and commercial revenue of 3.113 billion yuan, down 649 million yuan year-on-year [2] - Key products have seen a decrease in sales, with a non-recurring net profit dropping by 21.62% to 746 million yuan, indicating a fatigue in main business growth [2] - The complete divestment from Tianjin Sihke may pose challenges for Daren Tang in terms of strategic execution and the ability to cultivate new business opportunities [2] Group 4: Future Growth Considerations - The ability of Daren Tang to effectively utilize the proceeds from the sale to drive future growth will be critical [2] - Without a clear industrial logic and implementation path, there is a risk of resource waste and management challenges with the large sum of cash on hand [2] - The sale of Tianjin Sihke is seen as a starting point, with the real challenge lying in how to leverage the funds for the next growth phase [2]

Regulatory Developments - The National Medical Products Administration reported four cases of illegal online sales of medical devices, emphasizing a "zero tolerance" regulatory attitude to ensure safety in medical device usage [2] - Companies involved include Jiangyin Tianyu Medical Device Co., Yiwu Shenghe Medical Device Co., Shanghai Yile Warehouse Medical Device Co., and Hefei Baohua Design Studio, all of which failed to comply with regulatory requirements [2] Industry Advancements - Hangzhou is accelerating the development of medical artificial intelligence applications, aiming to establish a national AI (medical) application pilot base and create intelligent medical entities focused on various health management areas [3] - The city plans to build digital health innovation laboratories to advance key technologies in medical AI [3] Company Announcements - Leksin Medical received a medical device registration certificate for its wrist-type electronic blood pressure monitor from the Guangdong Provincial Drug Administration [5] - David Medical's wholly-owned subsidiary, Ningbo Yongxing Medical Instruments Co., obtained a medical device registration certificate for a linear cutting stapler used in various surgical procedures [6] - Warner Pharmaceuticals announced the approval of its drug registration certificate for the injection of methoxamine hydrochloride, used for treating acute hypotension during spinal anesthesia [7] Financial Reports - Guobang Pharmaceutical reported a revenue of 1.44 billion yuan for Q1 2025, a year-on-year increase of 7.57%, with a net profit of 215 million yuan, up 8.17% [9] - Johnson & Johnson's Q1 sales reached 21.89 billion dollars, with an annual sales forecast of 91 to 91.8 billion dollars and adjusted earnings per share projected between 10.50 and 10.70 dollars [10] Market Movements - In Hong Kong, InnoCare's stock surged by 130% on its first trading day [12] - Darentang announced plans to transfer a 12% stake in China-US Tianjin Schering Pharmaceutical Co., with estimated investment income of approximately 1.54 billion yuan from the transaction [13] - Nanjing Noling Biotechnology completed a C-round financing of several hundred million yuan, led by Dingxin Capital [14] Collaborative Initiatives - Berry Genomics' subsidiary signed a project cooperation framework agreement with Beijing Children's Hospital to promote clinical transformation and commercialization of research outcomes related to newborn screening technologies [16] - Bangyan Technology plans to officially launch its AI Agent product this year, aimed at assisting digital transformation in the healthcare sector [17] Personnel Changes - Bell Bio's financial officer, Zhao Baozhen, resigned for personal reasons but will continue to serve as the board secretary [19]

中美天津史克制药有限公司 2023 年 1 月-2024 年 12 月 财务报表审计报告 CAC审字[2025]0319号 中审华会计师事务所(特殊普通合伙) 审计报告 CAC 审字[2025]0319 号 津药达仁堂集团股份有限公司全体股东: 一、审计意见 我们审计了中美天津史克制药有限公司(以下简称中美史克)财务报表,包 括2023年12月31日、2024年12月31日的资产负债表,2023年度、2024年度利润表、 现金流量表、所有者权益变动表以及相关财务报表附注。 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://wc.mof.jpc.cn 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ac.mof.jpc.cn） 进行 ： 国 11:5 | 目 | 录 | 页 次 | | --- | --- | --- | | 一、审计报告 | | 1-3 | | 二、已审财务报表 | | | | 资产负债表 | | 4-2 | | 利润表 | | 6 | | 现金流量表 | | 7 | | 所有者权益变动表 | | 8-9 | | ແໃ 财务报表附注 | | 10- ...

证券代码：600329 证券简称：达仁堂 编号：临 2025-014 号 津药达仁堂集团股份有限公司 关于转让参股公司股权的交易公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、交易概述 津药达仁堂集团股份有限公司（以下简称"公司"）所属参股公 司中美天津史克制药有限公司（以下简称"天津史克"）是一家中外 合资有限责任公司，其股东构成为公司持有其 12%股份、Haleon UK Services Limited（以下简称"赫力昂（英国）"）持有其 55%股份、赫 力昂（中国）有限公司（以下简称"赫力昂（中国）"）持有其 33% 股份。现赫力昂（中国）与 Haleon CH SARL (CHE-102.429.188)（以 下简称"Haleon CH SARL"）积极寻求收购公司所持有的天津史克 12%股权，且其报价相较于资产评估价值有 35%溢价。基于该交易有 利于增加公司现金流入，且符合公司聚焦主业的发展思路，公司拟同 1 公司拟分别向赫力昂（中国）有限公司、Haleon CH SARL 转让所持有 ...

津药达仁堂集团股份有限公司于 2025 年 4 月 14 日以现场结合通 讯方式召开了 2025 年第二次董事会会议。本次会议应参加董事 9 人， 实参加董事 9 人。会议召开符合《公司法》、《证券法》和《公司章程》 有关召开董事会会议的规定。会议形成如下决议： 证券代码：600329 证券简称：达仁堂 编号：临 2025-013 号 津药达仁堂集团股份有限公司 2025 年第二次董事会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 上述第一项议案尚需提交公司 2025 年第一次临时股东大会审议 1 批准。 特此公告。 津药达仁堂集团股份有限公司董事会 一、审议通过了公司转让所持有中美天津史克制药有限公司 12% 股权暨签订《股权转让协议》的议案。（详见临时公告 2025-014 号） 公司拟分别向赫力昂（中国）有限公司转让所持有中美天津史克 制药有限公司 4.6%股权，转让价格 622,328,888.89 元人民币；向 Haleon CH SARL (CHE-102.429.188) 转让所持有中美天津史克制药 ...

证券代码：600329 证券简称：达仁堂 编号：临 2025-005 号 津药达仁堂集团股份有限公司 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任任。 公司于 2025 年 3 月 28 日以通讯方式召开 2025 年第一次监事会 会议，会议应到监事 3 名，实到监事 3 名。本次会议召开符合公司章 程的有关规定，经与会监事认真审议，形成如下决议： 一、审议通过了公司 2024 年度监事会工作报告。 表决结果：同意 3 票，反对 0 票，弃权 0 票 二、审核公司 2024 年度年报及摘要无误，并发表审核意见如下： 章程和公司内部管理制度的各项规定； 规定，所包含的信息从各个方面真实地反映出公司当年度的经营管理 和财务状况等事项； 反保密规定的行为。 表决结果：同意 3 票，反对 0 票，弃权 0 票 三、审核公司 2024 年度财务报告无误。 表决结果：同意 3 票，反对 0 票，弃权 0 票 四、审核公司 2024 年度利润分配预案无误。 监事会认为公司 2024 年度利润分配预案符合中国证监会、上海 证券交易所、新加坡交 ...

证券代码：600329 证券简称：达仁堂 公告编号：2025-012 号 津药达仁堂集团股份有限公司 关于召开 2024 年年度股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 召开地点：中国天津市南开区白堤路 17 号达仁堂大厦会议室 网络投票起止时间：自 2025 年 5 月 15 日 至 2025 年 5 月 15 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过 互联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 无 二、 会议审议事项 本次股东大会审议议案及投票股东类型 投票股东类型 序号 议案名称 A 股股东 非累积投票议案 新币"的议案 新币"的议案 币"的议案 民币"的议案 和结项、终止并将节余募集资金永久补充流动资 上述议案分别经公司 2025 年第一次董事会、2025 年第一次监事会审议 通过，相关公告于 20 ...

证券代码：600329 证券简称：达仁堂 编号：临 2025-006 号 津药达仁堂集团股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 每股分配比例：每股派发现金红利 1.28 元人民币（含税）。 （一）董事会会议的召开、审议和表决情况 （二）独立董事意见 独立董事认为，董事会提出的 2024 年度利润分配预案，综合考 虑了公司所处的行业特点、发展阶段、自身经营模式、未来发展资金 需求等多方面因素，符合公司的实际情况；董事会对于该项预案的审 议表决程序符合《公司法》 、《上市公司监管指引第 3 号——上市公司 现金分红》、《上海证券交易所上市公司自律监管指引第 1 号——规 范运作》及《公司章程》 经中审华会计师事务所审计（中国准则），本公司 2024 年度实现 净利润按中国会计准则核算为 2,060,471,830.44 元，公司年初累计未 分配利润 4,425,458,181.66 元，2024 年年度实施利润分配共计分配股 利 985,578,873.28 元。至此，本年累计可供全体股东 ...

津药达仁堂集团股份有限公司 CAC 2024 年财务报表审计报告 CAC 审 字 [2025]0340 号 | 索引 | | 页码 | | --- | --- | --- | | 审计报告 | | 1-6 | | 公司财务报表 | | | | — 合并资产负债表 | | 7-8 | | — | 母公司资产负债表 | 9-10 | | — 合并利润表 | | C 11 | | — 母公司利润表 | A | 12 | | — 合并现金流量表 | | 13 | | — | 母公司现金流量表 C | 14 | | — | 合并股东权益变动表 | 15-16 | | — | 母公司股东权益变动表 | 17-18 | | — 财务报表附注 | | 19-136 | CAC CAC CAC CAC CAC CAC CAC CAC CAC CAC CAC CAC CAC CAC | C A | | --- | | C C A C | | C A | | --- | | C A C | | C | | | | | C A C | | --- | | C A C | | C A | | --- | | C C A C | | C ...